ArticleThe Journal of cell biology2022
PD-LI promotes rear retraction during persistent cell migration by altering integrin β4 dynamics.
Article in The Journal of cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Migrasomes program tissue microenvironment: from physiology to oncology, future perspectives in clinical advances.Journal of the National Cancer Center · 2026Review
- Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma.Molecular oncology · 2026Article
- A decade of discovery: tracing the footmarks of migrasomes, unveiling the footprints of cells.Science China. Life sciences · 2026Review
- 3'UTR variants of ALS-linked RNAs modify subcellular and cellular phenotypes.The FEBS journal · 2026Article
- Super-Resolution Microscopy Reveals Nanoscale Arrangement of PD-L1 Immune Checkpoint.Chemical & biomedical imaging · 2026Article
- Kukoamine B Inhibits EMT in Lung Adenocarcinoma Cells by Regulating Intracellular PD-L1-Mediated p65 Nuclear Translocation.Biology · 2026Article
- Migrasomes: a journey from biogenesis to multifaceted roles in health and disease.Biomarker research · 2026Review
- Migrasome as a novel organelle: Biogenesis, physiological functions, and therapeutic potential.Journal of translational internal medicine · 2026Article
- Migrasomes constrained by a homologous-targeting photodynamic nanoplatform: enhancing intratumoral CD8Journal of nanobiotechnology · 2026Article
- Migrasomes: Emerging players in intercellular communication and disease pathogenesis (Review).Molecular medicine reports · 2026Review
- Integrating computational engines to identifyFrontiers in immunology · 2026Article
- Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment.Journal of biomedical science · 2025Review
- A decade of migrasome research: biogenesis, physiological functions, and disease implications.Cell research · 2025Review
- The biogenesis and biological roles of migrasomes in human diseases.Cell death discovery · 2025Review
- Cancer cell-derived migrasomes harboring ATF6 promote breast cancer brain metastasisCancer biology & medicine · 2025Article
- Review
- Migrasomes, critical players in intercellular communication.Cancer cell international · 2025Review
- Migrasomes: A New Role in Disease Diagnosis and Treatment.Biologics : targets & therapy · 2025Review
- Migrasomes: key players in immune regulation and promising medical applications.Frontiers in immunology · 2025Review
- Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates.Cell chemical biology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Although the immune checkpoint function of PD-L1 has dominated its study, we report that PD-L1 has an unanticipated intrinsic function in promoting the dynamics of persistent cell migration. PD-L1 concentrates at the rear of migrating carcinoma cells where it facilitates retraction, resulting in the formation of PD-L1-containing retraction fibers and migrasomes. PD-L1 promotes retraction by interacting with and localizing the β4 integrin to the rear enabling this integrin to stimulate contractility. This mechanism involves the ability of PD-L1 to maintain cell polarity and lower membrane tension at the cell rear compared with the leading edge that promotes the localized interaction of PD-L1 and the β4 integrin. This interaction enables the β4 integrin to engage the actin cytoskeleton and promote RhoA-mediated contractility. The implications of these findings with respect to cell-autonomous functions of PD-L1 and cancer biology are significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.